Poseida Therapeutics - PSTX Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $15.00
  • Forecasted Upside: 507.29%
  • Number of Analysts: 2
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 2 Buy Ratings
  • 0 Strong Buy Ratings
$2.47
▲ +0.1 (4.22%)

This chart shows the closing price for PSTX by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Poseida Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for PSTX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for PSTX

Analyst Price Target is $15.00
▲ +507.29% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for Poseida Therapeutics in the last 3 months. The average price target is $15.00, with a high forecast of $20.00 and a low forecast of $10.00. The average price target represents a 507.29% upside from the last price of $2.47.

This chart shows the closing price for PSTX for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 2 polled investment analysts is to buy stock in Poseida Therapeutics. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/12/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/10/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/8/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/6/2024
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/6/2024
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/4/2024
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/3/2024
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/2/2024

Latest Recommendations

  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
10/30/2024HC WainwrightReiterated RatingBuy ➝ Buy$20.00 ➝ $20.00
10/17/2024HC WainwrightReiterated RatingBuy ➝ Buy$20.00 ➝ $20.00
8/6/2024HC WainwrightReiterated RatingBuy ➝ Buy$20.00 ➝ $20.00
7/25/2024HC WainwrightReiterated RatingBuy ➝ Buy$20.00 ➝ $20.00
5/22/2024HC WainwrightReiterated RatingBuy ➝ Buy$20.00
5/2/2024HC WainwrightReiterated RatingBuy ➝ Buy$20.00
4/22/2024HC WainwrightReiterated RatingBuy ➝ Buy$20.00
12/11/2023Piper SandlerBoost TargetOverweight ➝ Overweight$8.00 ➝ $10.00
12/11/2023HC WainwrightBoost TargetBuy ➝ Buy$15.00 ➝ $20.00
10/10/2023Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$14.00
8/9/2023Cantor FitzgeraldLower Target$17.00 ➝ $14.00
8/8/2023HC WainwrightReiterated RatingBuy ➝ Buy$15.00
3/22/2023William BlairReiterated RatingOutperform
3/10/2023HC WainwrightReiterated RatingBuy$15.00
2/23/2023HC WainwrightReiterated RatingBuy$15.00
2/1/2023Cantor FitzgeraldReiterated RatingOverweight$24.00
1/4/2023HC WainwrightInitiated CoverageBuy$15.00
11/11/2022BTIG ResearchLower Target$20.00 ➝ $14.00
8/9/2022Piper SandlerBoost TargetOverweight$9.00 ➝ $11.00
5/13/2022Cantor FitzgeraldInitiated CoverageBuy$24.00
5/13/2022BTIG ResearchLower TargetBuy$40.00 ➝ $20.00
5/13/2022Piper SandlerLower Target$19.00 ➝ $9.00
5/9/2022Cantor FitzgeraldReiterated RatingOverweight
2/18/2022Cantor FitzgeraldInitiated CoverageBuy$24.00
1/7/2022Cantor FitzgeraldInitiated CoverageOverweight$24.00
10/12/2021Piper SandlerBoost TargetOverweight$17.00 ➝ $19.00
8/13/2021William BlairReiterated RatingOutperform
5/17/2021BTIG ResearchInitiated CoverageBuy$40.00
12/7/2020William BlairReiterated RatingBuy
9/16/2020William BlairReiterated RatingBuy
8/18/2020William BlairInitiated CoverageBuy
8/4/2020Bank of AmericaInitiated CoverageBuy$20.00
8/4/2020William BlairInitiated CoverageOutperform
8/4/2020Piper SandlerInitiated CoverageOverweight$30.00
(Data available from 11/2/2019 forward)

News Sentiment Rating

0.12 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 1 very positive mentions
  • 11 positive mentions
  • 3 negative mentions
  • 2 very negative mentions
4/6/2024
  • 1 very positive mentions
  • 16 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
5/6/2024
  • 3 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/5/2024
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/5/2024
  • 3 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
8/4/2024
  • 3 very positive mentions
  • 9 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
9/3/2024
  • 3 very positive mentions
  • 9 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
10/3/2024
  • 0 very positive mentions
  • 10 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
11/2/2024

Current Sentiment

  • 0 very positive mentions
  • 10 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
Poseida Therapeutics logo
Poseida Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for patients with high unmet medical needs. The company's development candidates for Heme Malignancies includes P-BCMA-ALLO1, which is in Phase I trial to treat patients with relapsed/refractory multiple myeloma; P-CD19CD20-ALLO1, which is in Phase I trial for treating B cell malignancies and other autoimmune diseases; P-BCMACD19-ALLO1, an allogeneic, off-the-shelf CAR-T product candidate in preclinical development for treating multiple myeloma; and P-CD70-ALLO1 under preclinical development to treat hematological indications. It is also involved in the development of P-MUC1C-ALLO1 that is in Phase I trial for treating a range of solid tumors, including breast, colorectal, lung, ovarian, pancreatic, and renal cancers; P-PSMA-ALLO1, an autologous chimeric antigen receptor T cell (CAR-T) product candidate that is in preclinical development for the treatment of patients with metastatic castrate resistant prostate cancer (mCRPC); and P-PSMA-101, an allogeneic CAR-T product candidate under Phase 1 clinical trial for treating mCRPC. In addition, the company engages in the development of P-FVIII-101, a clinical stage liver-directed gene therapy for the in vivo treatment of hemophilia A; P-OTC-101, a clinical stage liver-directed gene therapy for the in vivo treatment of ornithine transcarbamylase deficiency; and P-PAH-101, a clinical stage liver-directed gene therapy for the in vivo treatment of phenylketonuria. It has a research collaboration and license agreement with F. Hoffmann-La Roche Ltd, and Hoffmann-La Roche Inc. The company was incorporated in 2014 and is headquartered in San Diego, California.
Read More

Today's Range

Now: $2.47
Low: $2.39
High: $2.48

50 Day Range

MA: $2.76
Low: $2.37
High: $3.61

52 Week Range

Now: $2.47
Low: $1.87
High: $4.27

Volume

255,645 shs

Average Volume

555,861 shs

Market Capitalization

$239.92 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.51

Frequently Asked Questions

What sell-side analysts currently cover shares of Poseida Therapeutics?

The following Wall Street research analysts have issued research reports on Poseida Therapeutics in the last twelve months: HC Wainwright, and Piper Sandler.
View the latest analyst ratings for PSTX.

What is the current price target for Poseida Therapeutics?

2 Wall Street analysts have set twelve-month price targets for Poseida Therapeutics in the last year. Their average twelve-month price target is $15.00, suggesting a possible upside of 507.3%. HC Wainwright has the highest price target set, predicting PSTX will reach $20.00 in the next twelve months. Piper Sandler has the lowest price target set, forecasting a price of $10.00 for Poseida Therapeutics in the next year.
View the latest price targets for PSTX.

What is the current consensus analyst rating for Poseida Therapeutics?

Poseida Therapeutics currently has 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe PSTX will outperform the market and that investors should add to their positions of Poseida Therapeutics.
View the latest ratings for PSTX.

What other companies compete with Poseida Therapeutics?

How do I contact Poseida Therapeutics' investor relations team?

Poseida Therapeutics' physical mailing address is 9390 TOWNE CENTRE DRIVE SUITE 200, SAN DIEGO CA, 92121. The company's listed phone number is 858-779-3100 and its investor relations email address is [email protected]. The official website for Poseida Therapeutics is www.poseida.com. Learn More about contacing Poseida Therapeutics investor relations.